Measurable/Minimal Residual Disease: What Method and What Cut-Off?
1Haematological Malignancy Diagnostic Service (HMDS), Level 3, Bexley Wing, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK; Department of Epidemiology and Cancer Statistics (ECSG), University of York, Seebohm Rowntree Building, York, YO10 5DD, UK.
Minimal residual disease (MRD) testing is crucial for evaluating time-limited cancer treatments. This review guides the selection of appropriate MRD methods and thresholds for clinical use.
Area of Science:
- Hematology
- Oncology
- Clinical Diagnostics
Background:
- Minimal residual disease (MRD) testing is a key biomarker in clinical trials for time-limited treatments.
- MRD-guided treatment strategies are increasingly being evaluated in various cancers.
Purpose of the Study:
- To compare the technical and practical aspects of current MRD testing methods.
- To provide guidance on selecting the optimal MRD approach and threshold for different clinical scenarios.
Main Methods:
- Review and comparison of available MRD detection technologies.
- Analysis of practical considerations for implementation in clinical settings.
Main Results:
- Key technical features of different MRD assays are detailed.
- Practical considerations for method selection are discussed.
Conclusions:
- Appropriate selection of MRD methods and thresholds is essential for effective clinical application.
- Guidance is provided to aid clinicians in choosing the best MRD strategy for their patients.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
06:55Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells
Published on: February 22, 2020
Related Concept Videos
01:05Difference from Background: Limit of Detection
The LOD indicates the presence or absence...
01:24Kaplan-Meier Approach
01:09Truncation in Survival Analysis
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are observed.